Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 9/20 | 0.64 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.64 |
| ▸ | PGR | P06401 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5607587 | 1.00 | NR3C2 (0.64) | NR3C2NR3C1PGRALDH1A1TSHR | |
| SCHEMBL5607262 | 0.86 | ALDH1A1 (0.63) | NR3C2NR3C1ALDH1A1TSHRNPSR1 | |
| SCHEMBL5607265 | 0.86 | ALDH1A1 (0.63) | NR3C2NR3C1ALDH1A1TSHRNPSR1 | |
| SCHEMBL5608193 | 0.76 | LMNA (0.62) | ALDH1A1MAPT | |
| SCHEMBL27734522 | 0.75 | SLC1A3 (0.50) | ALDH1A1PKMMAPT | |
| SCHEMBL5607874 | 0.75 | SLC1A3 (0.50) | ALDH1A1PKMMAPT | |
| SCHEMBL5606910 | 0.75 | KMT2A (0.59) | ALDH1A1TSHRPKMMAPT | |
| SCHEMBL22636247 | 0.74 | BRD4 (0.57) | NR3C1PGRPKM | |
| SCHEMBL22636245 | 0.74 | BRD4 (0.57) | NR3C1PGRPKM | |
| SCHEMBL5607840 | 0.74 | KEAP1 (0.61) | ALDH1A1NPSR1PKMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101400699-A | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions | BRISTOL MYERS SQUIBB CO (US) | 2009-04-01 | — | — | CN | claimed |
| EP-1976873-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Brystol-Myers Squibb Company (US) | 2008-10-08 | — | — | EP | claimed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | claimed |
| WO-2007082264-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-19 | — | — | WO | claimed |
| CN-101400699-A | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions | BRISTOL MYERS SQUIBB CO (US) | 2009-04-01 | — | — | CN | disclosed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | disclosed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | disclosed |
| WO-2007082264-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | GLP1R, GIPR, IAPP | NR3C2 3201/4885NR3C1 2398/4885PGR 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.